research Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
GLP-1RAs, like semaglutide and tirzepatide, may cause hair loss, so patients should be informed and monitored.
Search
for
Sort by
Research
30-60 / 1000+ results research 44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
research 43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
research Pramipexole
Pramipexole can cause side effects like dizziness, sleepiness, hallucinations, and low blood pressure, and it's important to educate patients and keep doses low.
research Finasteride/spironolactone
research Table of Contents
Second-generation antipsychotics offer no significant benefit over first-generation ones for schizophrenia.
research Liarozole—a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate
Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
research Olanzapine Induced Hair Loss: A Case Report
Stopping the drug olanzapine can reverse hair loss caused by it.
research Repurposing FDA approved drugs for psoriasis indications through integrated molecular docking, one-SVM algorithm, and molecular dynamics simulation approaches
Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.
research Balancing metabolic optimization and reproductive safety in Polycystic Ovary Syndrome: a Bayesian-informed framework for GLP-1 receptor agonists
The document discusses the use of GLP-1 receptor agonists (GLP-1RAs) in managing Polycystic Ovary Syndrome (PCOS), focusing on their metabolic benefits rather than confirmed fertility enhancement. The narrative synthesis highlights the need for individualized treatment plans, emphasizing the distinction between metabolic optimization and reproductive outcomes. The study suggests GLP-1RAs should be used as short-term, preconception tools, with careful planning for drug discontinuation to avoid rebound effects. The authors call for future trials to standardize reproductive endpoints and capture periconception exposure to better assess the benefits and risks.
research Treatment of insulin resistance with tirzepatide leading to improvement of hair loss
Tirzepatide may improve hair loss by reducing insulin resistance.
research Enzalutamide/finasteride/goserelin/zoledronic-acid
research Hirsutism in a Female Adolescent Induced by Long-Acting Injectable Risperidone
A teenage girl's excessive hair growth was caused by a medication for mania, but improved after stopping the medication.
research Blockbuster Weight-Loss Drugs Not Tied to Suicidality, Studies Show
Weight-loss drugs are not linked to suicidal thoughts.
research Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review
GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.
research GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
research Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials
Extended-release divalproex is better tolerated and more effective for seizures and psychiatric symptoms than delayed-release divalproex, but doesn't reduce hair loss.
research Co-administration of 5α-reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids
Taking 5α-reductase inhibitors with prednisolone can worsen its negative effects on metabolism.
research Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends
GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.
research Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
Ixekizumab has known and some unexpected side effects.
research The Clinical Center’s Blood Glucose Management Service
The Blood Glucose Management Service improved patient safety and outcomes in managing blood sugar in hospitalized patients.
research Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome
Both metformin and pioglitazone improve PCOS symptoms, but pioglitazone is a good alternative for those who can't take metformin.
research Efalizumab-induced hypertrichosis
Efalizumab can cause unexpected excessive hair growth.
research Alfuzosin/finasteride
research Alfuzosin/finasteride
research 265 Modulation of disease-central cytokine pathways with TAK-279, a highly selective oral tyrosine kinase 2 (TYK2) inhibitor, defines clinical response in patients with psoriasis
TAK-279 effectively reduces psoriasis symptoms and is safe.
research Eosinophilia associated with clozapine – A case report
A patient's allergic reaction to clozapine resolved without stopping the medication, showing the importance of blood monitoring.
research Adverse Cutaneous Reactions to Antipsychotics
Some patients taking antipsychotic medications experience skin reactions, ranging from mild to severe.
research Dipyridamole-Associated Shock and Pulmonary Edema; Oxcarbazepine-Induced Resistant Ventricular Fibrillation; Finasteride-Induced Pseudoporphyria; Suicidal Ideation Associated with Asenapine; Rediscovering Adverse Anticholinergic Effects; Prevalence of Adverse Drug Events in Ambulatory Care
research Preclinical Development and Phase I Study of ZSYY001 , a Polymeric Micellar Paclitaxel for Advanced Solid Tumor
ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.